{"id":"NCT01112306","sponsor":"Actelion","briefTitle":"ACT-293987 in Pulmonary Arterial Hypertension","officialTitle":"Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07-07","primaryCompletion":"2021-08-26","completion":"2021-08-26","firstPosted":"2010-04-28","resultsPosted":"2022-09-19","lastUpdate":"2025-03-30"},"enrollment":709,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"ACT-293987","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation","timeFrame":"Up to 3 days after study drug discontinuation (Up to 10.5 years)","effectByArm":[{"arm":"Selexipag","deltaMin":684,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":157,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","India","Ireland","Israel","Malaysia","Mexico","Netherlands","Peru","Poland","Romania","Russia","Serbia","Singapore","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["34727317"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":420,"n":709},"commonTop":["Headache","Diarrhoea","Nausea","Pain in Jaw","Oedema Peripheral"]}}